NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
08/07/2026
Back to search
Official data from USPTO
ADDUCT PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ADDUCT PHARMACEUTICALS
ST13
US500000088244609Class
42
Filing
88244609
Registration
6082138
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
08/07/2026
Trademark type
Word
Nice classes
42
Filing date
12/28/2018
Registration date
06/16/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/07/2026
Last transaction
08/07/2026
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
02/03/2020
First use in commerce
02/03/2020
Drawing code
4
Owner type
03
Owner location
Ames, IA, US
Examiner
BERLIN, JUSTIN E
Current location
Historical data usage
Holders and representatives
Holders
MTI Biotech, Incorporated
Representatives
Emily Harris Dentons Davis Brown PC
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development in the field of PHARMACEUTICALSNUTRACEUTICALSNUTRITIONAL SUPPLEMENTS; Research and development in the pharmaceutical and biotechnology fields
Publications
History of USPTO decisions and trademark events.
35 publications found
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
08/07/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/07/2026
ES8R
TEAS SECTION 8 RECEIVED
06/12/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/16/2025
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
06/16/2020
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/09/2020
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
05/07/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
05/07/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/07/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
05/07/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/21/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/21/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/21/2020
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
03/11/2020
IUAA
USE AMENDMENT ACCEPTED
03/10/2020
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
03/10/2020
IUAF
USE AMENDMENT FILED
03/06/2020
EAAU
TEAS AMENDMENT OF USE RECEIVED
03/06/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/21/2019
GNFR
FINAL REFUSAL E-MAILED
10/21/2019
CNFR
FINAL REFUSAL WRITTEN
10/21/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/24/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/23/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/23/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
09/10/2019
ALIE
ASSIGNED TO LIE
09/05/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
08/30/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/21/2019
GNRT
NON-FINAL ACTION E-MAILED
03/21/2019
CNRT
NON-FINAL ACTION WRITTEN
03/21/2019
DOCK
ASSIGNED TO EXAMINER
03/19/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/19/2019
NWAP
NEW APPLICATION ENTERED
01/01/2019
Continuous trademark protection
Get notified about every new filing that threatens ADDUCT PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.